Protalix BioTherapeutics (PLX) Liabilities and Shareholders Equity (2010 - 2026)

Protalix BioTherapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $102.3 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 38.49% year-over-year to $102.3 million in Q1 2026; TTM through Mar 2026 was $345.4 million, a 14.99% increase from a year earlier, with the FY2025 full-year figure at $82.3 million, up 12.16% from the prior year.
• Liabilities and Shareholders Equity climbed to $102.3 million in Q1 2026 per PLX's latest filing, from $82.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $102.3 million in Q1 2026 and bottomed at $55.8 million in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $78.5 million (2025), against an average of $76.7 million.
• Across the five-year window, Liabilities and Shareholders Equity sank 43.96% in 2022 and surged 54.42% in 2023, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $55.8 million in 2022, then soared by 51.35% to $84.4 million in 2023, then fell by 13.05% to $73.4 million in 2024, then increased by 12.16% to $82.3 million in 2025, then grew by 24.28% to $102.3 million in 2026.
• Per Business Quant, the three latest PLX Liabilities and Shareholders Equity figures stand at $102.3 million (Q1 2026), $82.3 million (Q4 2025), and $82.3 million (Q3 2025).